8-K

ROYALTY PHARMA PLC

Date: January 8, 2024

/s/ Terrance Coyne

Terrance Coyne

Chief Financial Officer

0001193125-24-003879.txt : 20240108 0001193125-24-003879.hdr.sgml : 20240108 20240108071852 ACCESSION NUMBER: 0001193125-24-003879 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 24518327 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 d910834d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2024

Royalty Pharma plc

(Exact Name of Registrant as Specified in its Charter)

England and Wales

001-39329

98-1535773

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)


110 East 59^th Street
New York , New York		10022
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 883-0200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Class A Ordinary Shares, par value $0.0001 per share

RPRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On January 8, 2024, Royalty Pharma plc issued a press release providing a preliminary update on the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

99.1		Press release issued by Royalty Pharma plc, dated January 8, 2024

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EX-99.1 2 d910834dex991.htm EX-99.1 EX-99.1

Exhibit 99.1


				PRESS RELEASE

ROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

•

2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range

•

Announced transactions of $13 billion since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025

NEW YORK, NY, January 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer, will discuss these updates tomorrow as part of a webcast presentation at the 42^nd Annual J.P. Morgan Healthcare Conference to be held at 12:00 p.m. Eastern Time / 9:00 a.m. Pacific Time.

“Royalty Pharma delivered record performance in 2023,” said Pablo Legorreta. “We expect to achieve an all-time high for Portfolio Receipts of approximately $3.05 billion, representing our third consecutive year of double-digit underlying growth since our initial public offering in 2020. We deployed substantial capital to acquire royalties on eight therapies, including our strongest year ever for synthetic royalty transactions. We remain in an excellent position to deliver compounding growth in the years to come while executing on our mission and vision to accelerate innovation in life sciences and transform patient lives globally.”

Record 2023 Financial Performance

Based on preliminary unaudited fourth quarter 2023 results, Royalty Pharma now expects to deliver Portfolio Receipts for full year 2023 of approximately $3,050 million, which includes a $50 million payment related to oral zavegepant and exceeds the upper end of its previous guidance range of $2,950 million to $3,000 million. This represents underlying growth of 11% year-over-year prior to Biohaven-related payments and reflects the strong performance of Royalty Pharma’s diversified royalty portfolio. Royalty Pharma also expects Net cash provided by operating activities to be approximately $2,980 million to $2,990 million for full year 2023.

Portfolio Receipts was previously referred to as Adjusted Cash Receipts. The calculation of Portfolio Receipts will result in the same total as under Royalty Pharma’s previous presentation of Adjusted Cash Receipts. This change of presentation will facilitate increased transparency into the economics of individual royalties, as Royalty Receipts by product and franchise, will be reported net of legacy non-controlling interests.

Royalty Pharma’s preliminary unaudited fourth quarter 2023 results provided in this press release are subject to change in connection with the completion of the company’s final adjustments and other developments that may arise during the preparation and audit of its financial statements. Royalty Pharma’s management will host a conference call to discuss Royalty Pharma’s fourth quarter and full year 2023 results in February 2024.


				PRESS RELEASE

Strong Capital Deployment Added Innovative Therapies, Enhancing Long-term Growth

Since 2020, Royalty Pharma has announced transactions of approximately $13 billion, including $4.0 billion in 2023. Important additions to Royalty Pharma’s portfolio in the past year have included incremental royalties on Evrysdi, the fast-growing therapy for spinal muscular atrophy, as well as the potentially practice-changing, development-stage compounds pelacarsen for cardiovascular disease and KarXT for schizophrenia. Royalty Pharma also had its strongest year ever for synthetic royalties with announced transactions of $775 million, including Adstiladrin for bladder cancer, which is the first gene therapy added to its portfolio, Skytrofa, an approved therapy for growth hormone deficiency and TEV-‘749, an exciting development-stage compound for schizophrenia.

In total, 34 unique therapies have been added to the company’s portfolio since 2020 (of which 17 are either currently or projected to be blockbusters that generate annual sales of $1 billion or more based on consensus estimates). In aggregate, based on consensus sales forecasts, investments made since 2020 are estimated to add approximately $1.2 billion to Royalty Pharma’s Portfolio Receipts in 2025.

Biopharma Funding Environment Driving New Royalty Opportunities

The biopharmaceutical ecosystem is generating significant demand for capital to fund the ongoing wave of healthcare innovation. Reflecting this positive market backdrop, between 2019 and 2023, the number of in-depth reviews of new royalty opportunities conducted by Royalty Pharma increased by 133%, resulting in an 80% increase in announced annual transaction value (from $2.2 billion in 2019 to $4.0 billion in 2023).

Given Royalty Pharma’s unique role at the heart of funding life sciences innovation, Royalty Pharma believes that there will be significant opportunity to deploy capital and fund innovation, while creating value for its stakeholders. This is reflected in the company’s capital deployment target of $10 billion to $12 billion from 2022 to 2026 and in Royalty Pharma’s expectation that it has the potential over the longer term to double its average annual capital deployment to $4 billion to $5 billion.

Webcast of J.P. Morgan Healthcare Conference

Royalty Pharma will present at the 42^nd Annual J.P. Morgan Healthcare Conference at 12:00 p.m. ET / 9:00 a.m. PT tomorrow. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly—directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates.


				PRESS RELEASE

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “target,” “forecast,” “guidance,” “goal,” “predicts,” “project,” “potential” or “continue,”” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Portfolio Receipts

Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and Other Contractual Receipts. Royalty Receipts include variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that is attributed to Royalty Pharma.


				PRESS RELEASE

Milestones and Other Contractual Receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that is attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to our fundamental business strategy.

Portfolio Receipts is calculated as the sum of the following line items from our GAAP consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests—Portfolio Receipts, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to the legacy investors.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772

ir@royaltypharma.com

EX-101.SCH 3 rprx-20240108.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rprx-20240108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rprx-20240108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g910834g43d00.jpg GRAPHIC begin 644 g910834g43d00.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Jan. 08, 2024
Cover [Abstract]
Entity Address, State or Province	NY
Amendment Flag	false
Entity Central Index Key	0001802768
Document Type	8-K
Document Period End Date	Jan. 08, 2024
Entity Registrant Name	Royalty Pharma plc
Entity Incorporation State Country Code	X0
Entity File Number	001-39329
Entity Tax Identification Number	98-1535773
Entity Address, Address Line One	110 East 59th Street
Entity Address, City or Town	New York
Entity Address, Postal Zip Code	10022
City Area Code	(212)
Local Phone Number	883-0200
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol	RPRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 d910834d8k_htm.xml IDEA: XBRL DOCUMENT 0001802768 2024-01-08 2024-01-08 NY false 0001802768 8-K 2024-01-08 Royalty Pharma plc X0 001-39329 98-1535773 110 East 59th Street New York 10022 (212) 883-0200 false false false false Class A Ordinary Shares, par value $0.0001 per share RPRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d910834d8k.htm rprx-20240108.xsd rprx-20240108_lab.xml rprx-20240108_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d910834d8k.htm": { "nsprefix": "rprx", "nsuri": "http://royaltypharma.com/20240108", "dts": { "inline": { "local": [ "d910834d8k.htm" ] }, "schema": { "local": [ "rprx-20240108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "rprx-20240108_lab.xml" ] }, "presentationLink": { "local": [ "rprx-20240108_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-01-08_to_2024-01-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d910834d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-01-08_to_2024-01-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d910834d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://royaltypharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-24-003879-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-003879-xbrl.zip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�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end